<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">108870</article-id><article-id pub-id-type="doi">10.17816/dv108870</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Pathogenesis of psoriasis: past, present, future</article-title><trans-title-group xml:lang="ru"><trans-title>Патогенез псориаза: прошлое, настоящее, будущее</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0723-2800</contrib-id><contrib-id contrib-id-type="spin">8998-2307</contrib-id><name-alternatives><name xml:lang="en"><surname>Kandalova</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Кандалова</surname><given-names>Ольга Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>olga_kandalova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6595-1825</contrib-id><contrib-id contrib-id-type="spin">1809-7581</contrib-id><name-alternatives><name xml:lang="en"><surname>Klyuchnikova</surname><given-names>Dina E.</given-names></name><name xml:lang="ru"><surname>Ключникова</surname><given-names>Дина Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Assistant Lecturer</p></bio><bio xml:lang="ru"><p>к.м.н. ассистент</p></bio><email>dina_kl@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4495-3909</contrib-id><contrib-id contrib-id-type="spin">7894-8684</contrib-id><name-alternatives><name xml:lang="en"><surname>Ayvazova</surname><given-names>Tatyana V.</given-names></name><name xml:lang="ru"><surname>Айвазова</surname><given-names>Татьяна Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Assistant Lecturer</p></bio><bio xml:lang="ru"><p>к.м.н. ассистент</p></bio><email>aivazova_tatyana@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Moscow State University of Medicine and Dentistry named after A.I. Evdokimov</institution></aff><aff><institution xml:lang="ru">Московский государственный медико-стоматологический университет имени А.И. Евдокимова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-10-13" publication-format="electronic"><day>13</day><month>10</month><year>2022</year></pub-date><volume>25</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>191</fpage><lpage>200</lpage><history><date date-type="received" iso-8601-date="2022-06-20"><day>20</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-13"><day>13</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Эко-Вектор"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-08-01"/></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/108870">https://rjsvd.com/1560-9588/article/view/108870</self-uri><abstract xml:lang="en"><p>Psoriasis is a common, chronic, systemic immune-mediated inflammatory disease that affects the skin, joints, and other organs and systems. Despite the fact that psoriasis is one of the most studied dermatoses, its pathogenesis has not yet been fully clarified. In recent years, the pathogenetic model leading to the formation of psoriatic papules and plaques has undergone significant changes.</p> <p>This article presents a retrospective analysis of the study of the disease over the past 60 years from the generally accepted concept of epidermal dermatosis to understanding the complex interactions between keratinocytes, dendritic cells, T-lymphocytes, neutrophils and mast cells, with a significant role of interleukins (IL) 23, 17, 22,10, T-helper cells (Th) 17, 22, T-regulatory cells, transformative growth factor b1 (TGF-b1), in the pathogenesis of the disease. Targeted therapy using new biologics and small molecules, patient education, screening for comorbidities, and regular patient follow-up allow to apply a personalized approach to the patient and achieve impressive results.</p> <p>Achievements in psoriasis research have led to the fact that today we are witnessing the so-called translational revolution in psoriasis therapy, consisting in the fastest possible transfer of fundamental discoveries of the field of theoretical research to the field of practical application.</p></abstract><trans-abstract xml:lang="ru"><p>Псориаз представляет собой распространённое хроническое системное иммуноопосредованное воспалительное заболевание, поражающее кожу, суставы, другие органы и системы. Несмотря на то, что псориаз является одним из наиболее изученных дерматозов, его патогенез до сих пор до конца неясен. В последние годы патогенетическая модель, приводящая к образованию псориатических папул и бляшек, претерпела значительные изменения.</p> <p>В статье представлен ретроспективный анализ изучения заболевания за последние 60 лет от общепринятой концепции эпидермального дерматоза к пониманию сложных взаимодействий между кератиноцитами, дендритными клетками, Т-лимфоцитами, нейтрофилами и тучными клетками со значительной ролью интерлейкинов (IL) 23, 17, 22, 10, Т-хелперных клеток (Th) 17, 22, T-регуляторных клеток, трансформирующего фактора роста b1 в патогенезе заболевания. Таргетная терапия с использованием новых биологических препаратов и малых молекул, обучение пациента, скрининг сопутствующих заболеваний и регулярный мониторинг состояния пациента позволяют применять персонифицированный подход к пациенту и добиваться впечатляющих результатов.</p> <p>Достижения в изучении псориаза привели к тому, что сегодня мы наблюдаем так называемую трансляционную революцию в терапии заболевания, заключающуюся в максимально быстром переносе фундаментальных открытий из сферы теоретических исследований в сферу практического применения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>study history</kwd><kwd>pathogenesis</kwd><kwd>genetic factors</kwd><kwd>immunopathology</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>история изучения</kwd><kwd>патогенез</kwd><kwd>генетические факторы</kwd><kwd>иммунопатология</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997): 983–994. doi: 10.1016/S0140-6736(14)61909-7</mixed-citation><mixed-citation xml:lang="ru">Boehncke W.H., Schön M.P. Psoriasis // Lancet. 2015. Vol. 386, N 9997. Р. 983–994. doi: 10.1016/S0140-6736(14)61909-7</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Al Qassimi S, Al Brashdi S, Galadari H, Hashim MJ. Global burden of psoriasis ― comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–571. doi: 10.1111/ijd.14864</mixed-citation><mixed-citation xml:lang="ru">Al Qassimi S., Al Brashdi S., Galadari H., Hashim M.J. Global burden of psoriasis ― comparison of regional and global epidemiology, 1990 to 2017 // Int J Dermatol. 2020. Vol. 59, N 5. Р. 566–571. doi: 10.1111/ijd.14864</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Parisi R, Iskandar IY, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590</mixed-citation><mixed-citation xml:lang="ru">Parisi R., Iskandar I.Y., Kontopantelis E., et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study // BMJ. 2020. Vol. 369. Р. m1590. doi: 10.1136/bmj.m1590</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi: 10.1016/S0140-6736(07)61128-3</mixed-citation><mixed-citation xml:lang="ru">Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis // Lancet. 2007. Vol. 370, N 9583. Р. 263–271. doi: 10.1016/S0140-6736(07)61128-3</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064</mixed-citation><mixed-citation xml:lang="ru">Takeshita J., Grewal S., Langan S.M., et al. Psoriasis and comorbid diseases: Epidemiology // J Am Acad Dermatol. 2017. Vol. 76, N 3. Р. 377–390. doi: 10.1016/j.jaad.2016.07.064</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi: 10.1001/jama.296.14.1735</mixed-citation><mixed-citation xml:lang="ru">Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis // JAMA. 2006. Vol. 296, N 14. Р. 1735–1741. doi: 10.1001/jama.296.14.1735</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012;33(16):2054–2064. doi: 10.1093/eurheartj/ehr285</mixed-citation><mixed-citation xml:lang="ru">Ahlehoff O., Gislason G.H., Jørgensen C.H., et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study // Eur Heart J. 2012. Vol. 33, N 16. Р. 2054–2064. doi: 10.1093/eurheartj/ehr285</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Fernandez A.P. Dermatology update: the dawn of targeted treatment. Cleveland Clinic J Med. 2015;82(5):309–320. doi: 10.3949/ccjm.82gr.15002</mixed-citation><mixed-citation xml:lang="ru">Fernandez A.P. Dermatology update: the dawn of targeted treatment // Cleveland Clinic J Med. 2015. Vol. 82, N 5. Р. 309–320. doi: 10.3949/ccjm.82gr.15002</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Weinstein GD, McCullough JL. Cytokinetics and chemotherapy of psoriasis. J Invest Dermatol. 1976;67(1):26–30. doi: 10.1111/1523-1747.ep12512476</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Weinstein GD, Frost P. Abnormal cell proliferation in psoriasis. J Invest Dermatol. 1968;50(3):254–259.</mixed-citation><mixed-citation xml:lang="ru">Weinstein G.D., Frost P. Abnormal cell proliferation in psoriasis // J Invest Dermatol. 1968. Vol. 50, N 3. Р. 254–259.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Voorhees JJ, Duell EA, Bass LJ, et al. The cyclic AMP system in normal and psoriatic epidermis. J Invest Dermatol. 1972;59(1): 114–120. doi: 10.1111/1523-1747.ep12625885</mixed-citation><mixed-citation xml:lang="ru">Voorhees J.J., Duell E.A., Bass L.J., et al. The cyclic AMP system in normal and psoriatic epidermis // J Invest Dermatol. 1972. Vol. 59, N 1. Р. 114–120. doi: 10.1111/1523-1747.ep12625885</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Rusin LJ, Duell EA, Voorhees JJ. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro. J Invest Dermatol. 1978;71(2):154–156. doi: 10.1111/1523-1747.ep12546928</mixed-citation><mixed-citation xml:lang="ru">Rusin L.J., Duell E.A., Voorhees J.J. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro // J Invest Dermatol. 1978. Vol. 71, N 2. Р. 154–156. doi: 10.1111/1523-1747.ep12546928</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015;135(11):2641–2648. doi: 10.1038/jid.2015.206</mixed-citation><mixed-citation xml:lang="ru">Nast A., Jacobs A., Rosumeck S., Werner R.N. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis // J Invest Dermatol. 2015. Vol. 135, N 11. Р. 2641–2648. doi: 10.1038/jid.2015.206</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Perlamutrov YN, Aivazova TV, Olkhovskaya KB, Soloviev AM. Modern possibilities of systemic therapy of psoriasis. Russ J Clin Dermatology Venereology. 2019;18(4):474–478. (In Russ). doi: 10.17116/klinderma201918041474</mixed-citation><mixed-citation xml:lang="ru">Перламутров Ю.Н., Айвазова Т.В., Ольховская К.Б., Соловьев А.М. Современные возможности системной терапии псориаза // Клиническая дерматология и венерология. 2019. Т. 18, № 4. С. 474–447. doi: 10.17116/klinderma201918041474</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Brain S, Camp R, Dowd P, et al. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol. 1984;83(1):70–73. doi: 10.1111/1523-1747.ep12261712</mixed-citation><mixed-citation xml:lang="ru">Brain S., Camp R., Dowd P., et al. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis // J Invest Dermatol. 1984. Vol. 83, N 1. Р. 70–73. doi: 10.1111/1523-1747.ep12261712</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang H, Hou W, Henrot L, et al. Modelling epidermis homoeostasis and psoriasis pathogenesis. J R Soc Interface. 2015;12(103):20141071. doi: 10.1098/rsif.2014.1071</mixed-citation><mixed-citation xml:lang="ru">Zhang H., Hou W., Henrot L., et al. Modelling epidermis homoeostasis and psoriasis pathogenesis // J R Soc Interface. 2015. Vol. 12, N 103. Р. 20141071. doi: 10.1098/rsif.2014.1071</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Kim SA, Ryu YW, Kwon JI, et al. Differential expression of cyclin D1, Ki-67, pRb, and p53 in psoriatic skin lesions and normal skin. Mol Med Rep. 2018;17(1):735–742. doi: 10.3892/mmr.2017.8015</mixed-citation><mixed-citation xml:lang="ru">Kim S.A., Ryu Y.W., Kwon J.I., et al. Differential expression of cyclin D1, Ki-67, pRb, and p53 in psoriatic skin lesions and normal skin // Mol Med Rep. 2018. Vol. 17, N 1. Р. 735–742. doi: 10.3892/mmr.2017.8015</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Hwang YJ, Na JI, Byun SY, et al. Histone deacetylase 1 and sirtuin 1 expression in psoriatic skin: a comparison between guttate and plaque psoriasis. Life (Basel). 2020;10(9):157. doi: 10.3390/life10090157</mixed-citation><mixed-citation xml:lang="ru">Hwang Y.J., Na J.I., Byun S.Y., et al. Histone deacetylase 1 and sirtuin 1 expression in psoriatic skin: a comparison between guttate and plaque psoriasis // Life (Basel). 2020. Vol. 10, N 9. Р. 157. doi: 10.3390/life10090157</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang X, Yin M, Zhang LJ. Keratin 6, 16 and 17-critical barrier alarmin molecules in skin wounds and psoriasis. Cells. 2019;8(8):807. doi: 10.3390/cells8080807</mixed-citation><mixed-citation xml:lang="ru">Zhang X., Yin M., Zhang L.J. Keratin 6, 16 and 17-critical barrier alarmin molecules in skin wounds and psoriasis // Cells. 2019. Vol. 8, N 8. Р. 807. doi: 10.3390/cells8080807</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Nickoloff BJ, Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol. 1991;127:871–884.</mixed-citation><mixed-citation xml:lang="ru">Nickoloff B.J., Nickoloff B.J. The cytokine network in psoriasis // Arch Dermatol. 1991. Vol. 127, N 6. Р. 871–884.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101(5):701–705. doi: 10.1111/1523-1747.ep12371679</mixed-citation><mixed-citation xml:lang="ru">Uyemura K., Yamamura M., Fivenson D.F., et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response // J Invest Dermatol. 1993. Vol. 101, N 5. Р. 701–705. doi: 10.1111/1523-1747.ep12371679</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Pinegin BV, Ivanov L., Pinegin VB. The role of immune system cells and cytokines in the development of psoriasis. Russ J Skin Venereal Diseases. 2013;(3):19–25. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Пинегин Б.В., Иванов О.Л., Пинегин В.Б. Роль клеток иммунной системы и цитокинов в развитии псориаза // Российский журнал кожных и венерических болезней. 2013. № 3. С. 19–25.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150. doi: 10.1016/j.jaad.2013.12.036</mixed-citation><mixed-citation xml:lang="ru">Lynde C.W., Poulin Y., Vender R., et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis // J Am Acad Dermatol. 2014. Vol. 71, N 1. Р. 141–150. doi: 10.1016/j.jaad.2013.12.036</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Leonardi CL, Powers JL, Matheson RT, et al.; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;20;349(21):2014–2022. doi: 10.1056/NEJMoa030409</mixed-citation><mixed-citation xml:lang="ru">Leonardi C.L., Powers J.L., Matheson R.T., et al.; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis // N Engl J Med. 2003. Vol. 349, N 21. Р. 2014–2022. doi: 10.1056/NEJMoa030409</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Leonardi CL, Kimball AB, Papp KA, et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. doi: 10.1016/S0140-6736(08)60725-4</mixed-citation><mixed-citation xml:lang="ru">Leonardi C.L., Kimball A.B., Papp K.A., et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) // Lancet. 2008. Vol. 371, N 9625. Р. 1665–1674. doi: 10.1016/S0140-6736(08)60725-4</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014;33(2 Suppl 2):S37–41. doi: 10.12788/j.sder.0066</mixed-citation><mixed-citation xml:lang="ru">Leonardi C.L., Gordon K.B. New and emerging therapies in psoriasis // Semin Cutan Med Surg. 2014. Vol. 33, N 2, Suppl 2. Р. S37–41. doi: 10.12788/j.sder.0066</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199. doi: 10.1056/NEJMoa1109997</mixed-citation><mixed-citation xml:lang="ru">Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis // N Engl J Med. 2012. Vol. 366, N 13. Р. 1190–1199. doi: 10.1056/NEJMoa1109997</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Papp A, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189. doi: 10.1056/NEJMoa1109017</mixed-citation><mixed-citation xml:lang="ru">Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis // N Engl J Med. 2012. Vol. 366. Р. 1181–1189. doi: 10.1056/NEJMoa1109017</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi: 10.1007/s12016-018-8702-3</mixed-citation><mixed-citation xml:lang="ru">Blauvelt A., Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis // Clin Rev Allergy Immunol. 2018. Vol. 55, N 3. Р. 379–390. doi: 10.1007/s12016-018-8702-3</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Olisova OY, Anpilogova EM. Systemic treatment of psoriasis: from methotrexate to biologics. Bulletin Dermatology Venereology. 2020;96(3):7–26. (In Russ). doi: 10.25208/vdv1162</mixed-citation><mixed-citation xml:lang="ru">Олисова О.Ю., Анпилогова Е.М. Системная терапия псориаза: от метотрексата до генно-инженерных биологических препаратов // Вестник дерматологии и венерологии. 2020. Т. 96, № 3. C. 7–26. doi: 10.25208/vdv1162</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Piro MC, Ventura A, Smirnov A, et al. Transglutaminase 3 reduces the severity of psoriasis in imiquimod-treated mouse skin. Int J Mol Sci. 2020;21(5):1566. doi: 10.3390/ijms21051566</mixed-citation><mixed-citation xml:lang="ru">Piro M.C., Ventura A., Smirnov A., et al. Transglutaminase 3 reduces the severity of psoriasis in imiquimod-treated mouse skin // Int J Mol Sci. 2020. Vol. 21, N 5. Р. 1566. doi: 10.3390/ijms21051566</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Matsuki M, Yamashita F, Ishida-Yamamoto A, et al. Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase). Proc Natl Acad Sci USA. 1998;95(3):1044–1049. doi: 10.1073/pnas.95.3.1044</mixed-citation><mixed-citation xml:lang="ru">Matsuki M., Yamashita F., Ishida-Yamamoto A., et al. Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase) // Proc Natl Acad Sci USA. 1998. Vol. 95, N 3. Р. 1044–1049. doi: 10.1073/pnas.95.3.1044</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Tian S, Krueger JG, Li K, et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease. PLoS One. 2012;7(9):e44274. doi: 10.1371/journal.pone.0044274</mixed-citation><mixed-citation xml:lang="ru">Tian S., Krueger J.G., Li K., et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease // PLoS One. 2012. Vol. 7, N 9. Р. e44274. doi: 10.1371/journal.pone.0044274</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Suárez-Fariñas M, Li K, Fuentes-Duculan J, et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(11):2552–2564. doi: 10.1038/jid.2012.184</mixed-citation><mixed-citation xml:lang="ru">Suárez-Fariñas M., Li K., Fuentes-Duculan J., et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis // J Invest Dermatol. 2012. Vol. 132, N 11. Р. 2552–2564. doi: 10.1038/jid.2012.184</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi: 10.1101/cshperspect.a015354</mixed-citation><mixed-citation xml:lang="ru">Di Meglio P., Villanova F., Nestle F.O. Psoriasis // Cold Spring Harb Perspect Med. 2014. Vol. 4, N 8. Р. a015354. doi: 10.1101/cshperspect.a015354</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. doi: 10.1016/j.jaut.2015.07.008</mixed-citation><mixed-citation xml:lang="ru">Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of psoriasis: a comprehensive review // J Autoimmun. 2015. Vol. 64. Р. 66–73. doi: 10.1016/j.jaut.2015.07.008</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012;39(3):225–230. doi: 10.1111/j.1346-8138.2011.01483.x</mixed-citation><mixed-citation xml:lang="ru">Morizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis // J Dermatol. 2012. Vol. 39, N 3. Р. 225–230. doi: 10.1111/j.1346-8138.2011.01483.x</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Morizane S, Yamasaki K, Mühleisen B, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012;132(1): 135–143. doi: 10.1038/jid.2011.259</mixed-citation><mixed-citation xml:lang="ru">Morizane S., Yamasaki K., Mühleisen B., et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands // J Invest Dermatol. 2012. Vol. 132, N 1. Р. 135–143. doi: 10.1038/jid.2011.259</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Peltonen S, Riehokainen J, Pummi K, Peltonen J. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br J Dermatol. 2007;156:466–472. doi: 10.1111/j.1365-2133.2006.07642.x</mixed-citation><mixed-citation xml:lang="ru">Peltonen S., Riehokainen J., Pummi K., Peltonen J. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis // Br J Dermatol. 2007. Vol. 156. Р. 466–472. doi: 10.1111/j.1365-2133.2006.07642.x</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Kirschner N, Poetzl C, von den Driesch P, et al. Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am J Pathol. 2009;175(3):1095–1106. doi: 10.2353/ajpath.2009.080973</mixed-citation><mixed-citation xml:lang="ru">Kirschner N., Poetzl C., von den Driesch P., et al. Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines // Am J Pathol. 2009. Vol. 175, N 3. Р. 1095–1106. doi: 10.2353/ajpath.2009.080973</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Visconti B, Paolino G, Carotti S, et al. Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin. J Eur Acad Dermatol Venereol. 2015;29(10):2038–2042. doi: 10.1111/jdv.12736</mixed-citation><mixed-citation xml:lang="ru">Visconti B., Paolino G., Carotti S., et al. Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin // J Eur Acad Dermatol Venereol. 2015. Vol. 29, N 10. Р. 2038–2042. doi: 10.1111/jdv.12736</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Montero-Vilchez T, Segura-Fernández-Nogueras MV, Pérez-Rodríguez I, et al. Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful tools to assess disease severity. J Clin Med. 2021;10(2):359. doi: 10.3390/jcm10020359</mixed-citation><mixed-citation xml:lang="ru">Montero-Vilchez T., Segura-Fernández-Nogueras M.V., Pérez-Rodríguez I., et al. Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful tools to assess disease severity // J Clin Med. 2021. Vol. 10, N 2. Р. 359. doi: 10.3390/jcm10020359</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2): 104–110. doi: 10.1111/j.1600-0625.2011.01412.x</mixed-citation><mixed-citation xml:lang="ru">Gutowska-Owsiak D., Schaupp A.L., Salimi M., et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion // Exp Dermatol. 2012. Vol. 21, N 2. Р. 104–110. doi: 10.1111/j.1600-0625.2011.01412.x</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol. 2020;92(4):e12945. doi: 10.1111/sji.12945</mixed-citation><mixed-citation xml:lang="ru">Ten Bergen L.L., Petrovic A., Aarebrot A.K., Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis // Scand J Immunol. 2020. Vol. 92, N 4. Р. e12945. doi: 10.1111/sji.12945</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. doi: 10.1016/j.coi.2017.07.007</mixed-citation><mixed-citation xml:lang="ru">Liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: a mixed autoimmune and autoinflammatory disease // Curr Opin Immunol. 2017. Vol. 49. Р. 1–8. doi: 10.1016/j.coi.2017.07.007</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Orsmond A, Bereza-Malcolm L, Lynch T, et al. Skin barrier dysregulation in psoriasis. Int J Mol Sci. 2021;22(19):10841. doi: 10.3390/ijms221910841</mixed-citation><mixed-citation xml:lang="ru">Orsmond A., Bereza-Malcolm L., Lynch T., et al. Skin barrier dysregulation in psoriasis // Int J Mol Sci. 2021. Vol. 22, N 19. Р. 10841. doi: 10.3390/ijms221910841</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol. 2004;138(1):83–93. doi: 10.1111/j.1365-2249.2004.00600.x</mixed-citation><mixed-citation xml:lang="ru">Johnston A., Gudjonsson J.E., Sigmundsdottir H., et al. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells // Clin Exp Immunol. 2004. Vol. 138, N 1. Р. 83–93. doi: 10.1111/j.1365-2249.2004.00600.x</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Cheung KL, Jarrett R, Subramaniam S, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med. 2016;213(11):2399–2412. doi: 10.1084/jem.20160258</mixed-citation><mixed-citation xml:lang="ru">Cheung K.L., Jarrett R., Subramaniam S., et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a // J Exp Med. 2016. Vol. 213, N 11. Р. 2399–2412. doi: 10.1084/jem.20160258</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Méndez-Samperio P. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections. Peptides. 2010;31(9):1791–1798. doi: 10.1016/j.peptides.2010.06.016</mixed-citation><mixed-citation xml:lang="ru">Méndez-Samperio P. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections // Peptides. 2010. Vol. 31, N 9. Р. 1791–1798. doi: 10.1016/j.peptides.2010.06.016</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">Chiba H, Michibata H, Wakimoto K, et al. Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2 delta, induced in psoriatic skin. J Biol Chem. 2004;279(13):12890–12897. doi: 10.1074/jbc.M305801200</mixed-citation><mixed-citation xml:lang="ru">Chiba H., Michibata H., Wakimoto K., et al. Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2 delta, induced in psoriatic skin // J Biol Chem. 2004. Vol. 279, N 13. Р. 12890–12897. doi: 10.1074/jbc.M305801200</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Bragulla HH, Homberger DG. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. J Anat. 2009;214(4):516–559. doi: 10.1111/j.1469-7580.2009.01066.x</mixed-citation><mixed-citation xml:lang="ru">Bragulla H.H., Homberger D.G. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia // J Anat. 2009. Vol. 214, N 4. Р. 516–559. doi: 10.1111/j.1469-7580.2009.01066.x</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Besgen P, Trommler P, Vollmer S, Prinz JC. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis. J Immunol. 2010;184(9):5392–5402. doi: 10.4049/jimmunol.0903520</mixed-citation><mixed-citation xml:lang="ru">Besgen P., Trommler P., Vollmer S., Prinz J.C. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis // J Immunol. 2010. Vol. 184, N 9. Р. 5392–5402. doi: 10.4049/jimmunol.0903520</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–569. doi: 10.1038/nature06116</mixed-citation><mixed-citation xml:lang="ru">Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide // Nature. 2007. Vol. 449, N 7162. Р. 564–569. doi: 10.1038/nature06116</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Ganguly D, Chamilos G, Lande R, et al. Self-RNAantimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–1994. doi: 10.1084/jem.20090480</mixed-citation><mixed-citation xml:lang="ru">Ganguly D., Chamilos G., Lande R., et al. Self-RNAantimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 // J Exp Med. 2009. Vol. 206, N 9. Р. 1983–1994. doi: 10.1084/jem.20090480</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Lande R, Botti E, Jandus C, et al. Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2015;6:6595. doi: 10.1038/ncomms7595</mixed-citation><mixed-citation xml:lang="ru">Lande R., Botti E., Jandus C., et al. Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis // Nat Commun. 2015. Vol. 6. Р. 6595. doi: 10.1038/ncomms7595</mixed-citation></citation-alternatives></ref></ref-list></back></article>
